Abstract:Current anticancer drug development strategies involve identifying novel molecular targets which are crucial for tumourigenesis. The molecular chaperone heat shock protein (HSP) 90 is of interest as an anticancer drug target because of its importance in maintaining the conformation, stability and function of key oncogenic client proteins involved in signal transduction pathways leading to proliferation, cell cycle progression and apoptosis, as well as other features of the malignant phenotype such as invasion, angiogenesis and metastasis. The natural product HSP90 inhibitors geldanamycin and radicicol exert their antitumour effect by inhibiting the intrinsic ATPase activity of HSP90, resulting in degradation of HSP90 client proteins via the ubiquitin proteosome pathway. Anticancer selectivity may derive from the simultaneous combinatorial effects of HSP90 inhibitors on multiple cancer targets and pathways. 17-allylamino, 17-demethoxygeldanamycin (17AAG), a geldanamycin derivative, showed good activity and cancer selectivity in preclinical models and has now progressed to Phase I clinical trial in cancer patients with encouraging initial results. Phase II trials including combination studies with cytotoxic agents are now being planned and these should allow the therapeutic activity of 17AAG to be determined. Second generation HSP90 inhibitors may be designed to overcome some of the drawbacks of 17AAG, including limited oral bioavailability and solubility. They could also be engineered to target specific functions of HSP90, which may not only provide greater molecular selectivity and clinical benefit but may also increase understanding of the complex functions of this molecular chaperone. HSP90 inhibitors provide proof of concept for drugs directed at HSP90 and protein folding and this principle may be applicable to other medical conditions involving protein aggregation and stability.

Targeting HSP90 in Gynecologic Cancer: Molecular Mechanisms and Therapeutic Approaches

Targeting HSP90 as a Novel Therapy for Cancer: Mechanistic Insights and Translational Relevance

Functional and therapeutic significant of heat-shock protein 90 (HSP90) in reproductive cancers

Targeting HSP90 for Cancer Therapy: Current Progress and Emerging Prospects

Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy

HSP60-regulated Mitochondrial Proteostasis and Protein Translation Promote Tumor Growth of Ovarian Cancer

HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review)

New developments in Hsp90 inhibitors as anti-cancer therapeutics: Mechanisms, clinical perspective and more potential

HSP90 multi-functionality in cancer

Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress

Mechanisms of Action of HSP110 and Its Cognate Family Members in Carcinogenesis

Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer

Molecular Chaperone GRP94/GP96 in Cancers: Oncogenesis and Therapeutic Target

HSP90 and Co-chaperones: Impact on Tumor Progression and Prospects for Molecular-Targeted Cancer Therapy

HSP90 and the chaperoning of cancer

HSP70 and HSP90 in Cancer: Cytosolic, Endoplasmic Reticulum and Mitochondrial Chaperones of Tumorigenesis

The development of cancers research based on mitochondrial heat shock protein 90

HSP90 as a new therapeutic target for cancer therapy: the story unfolds

Targeting chaperones in transformed systems – a focus on Hsp90 and cancer

Targeting HSP70: The second potentially druggable heat shock protein and molecular chaperone?